*-*

Glenmark to raise $250 mn

Mumbai: Glenmark Pharmaceuticals Friday said the shareholders of the company have agreed to raise $250 million.

The company would raise the amount through global depository receipts, American depository receipts and foreign currency convertible bonds or by private placement of shares or by qualified institutional investors, Glenmark said in a statement.

*-*

Orchid gets US approval for Zaleplon capsules

Chennai: City-based Orchid Chemicals has received the final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Zaleplon Capsules.

With this approval, the total ANDA approval count of Orchid has gone up to 37, while the total ANDA filings stand at 58, the company said.

*-*

3i Infotech to raise Rs.500 crore

Mumbai: IT solutions provider 3i Infotech Friday said it will issue shares through qualified institutional placement (QIP) to raise around Rs.500 crore.

The committee of directors Thursday decided to launch the issue, 3i said in a regulatory statement.